---
title: "Dyne Therapeutics (DYN) Gets a Buy from LifeSci Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286648971.md"
description: "LifeSci Capital analyst Francois Brisebois has maintained a Buy rating on Dyne Therapeutics (DYN) with a price target of $44.00. Brisebois, a 3-star analyst, has an average return of 2.4% and a 40.11% success rate. Dyne Therapeutics also received a Buy rating from Evercore ISI, while Bernstein assigned a Hold rating on May 13."
datetime: "2026-05-16T14:36:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286648971.md)
  - [en](https://longbridge.com/en/news/286648971.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286648971.md)
---

# Dyne Therapeutics (DYN) Gets a Buy from LifeSci Capital

LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Dyne Therapeutics today and set a price target of $44.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Brisebois is a 3-star analyst with an average return of 2.4% and a 40.11% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Praxis Precision Medicines, and Opus Genetics.

In addition to LifeSci Capital, Dyne Therapeutics also received a Buy from Evercore ISI’s Gavin Clark-Gartner in a report issued yesterday. However, on May 13, Bernstein assigned a Hold rating to Dyne Therapeutics (NASDAQ: DYN).

### Related Stocks

- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)
- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)
- [IRD.US](https://longbridge.com/en/quote/IRD.US.md)

## Related News & Research

- [Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 3,311 Shares](https://longbridge.com/en/news/286472443.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)